Precision Biosensor, Inc (335810) Fair Value & Analysis
Healthcare · KR · Market cap 19.3B KRW
Fair value as of: Jul 9, 2026
From 1 valuation models · updated today
Fair value updated Jul 9, 2026 — revised from 5,078 KRW to 194.70 KRW (−96.2%) since Jun 24, 2026. Share price −12.6% over the past month.
Price vs Fair Value (12 months)
12‑month range 1,373 KRW – 3,510 KRW · fair‑value band 128.50 KRW – 243.38 KRW · the 1,442 KRW price screens above the 194.70 KRW fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Precision Biosensor, Inc (335810) currently trades at 1,442 KRW, while our model-based Fair Value estimate is 194.70 KRW — implying the stock looks roughly 86.5% overvalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Precision Biosensor, Inc generated revenue of 22.3B KRW at a net margin of -35.3%. Revenue grew 52.2% year over year. It earns a return on equity of -23.6%. Net debt stands at 10.1B KRW. Fundamentals as of Jul 9, 2026
Our scenario range runs from 128.50 KRW (bear case) to 243.38 KRW (bull case); at 1,442 KRW, the current price sits above that range. The share trades about 68% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside — at -86%, 335810 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
Precision Biosensor, Inc. engages in the development, production, and sale of immune diagnostic kits in South Korea. It offers Exdia TRF Plus, an immunodiagnosis POCT platform; and Exdia PT10 and Exdia PT10S, a clinical chemistry POCT platform. The company was founded in 2009 and is headquartered in Daejeon, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Precision Biosensor, Inc reported revenue of 19.9B KRW in FY2025 versus 15.9B KRW in FY2021, a compound +5.8%/yr. Reported net income was −10.0B KRW in FY2025.
Is 335810 fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EW | $87.45 | $41.02 | -53% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥143.50 | ¥111.50 | -22% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Precision Biosensor, Inc (335810) undervalued?
What is the fair value of 335810?
What is the quality score of 335810?
What is the revenue of Precision Biosensor, Inc (335810)?
What is the net profit margin of 335810?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.